CENTOGENE N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4889 USD | +1.88% |
|
+7.24% | -59.26% |
| Apr. 02 | Centogene Gets Nasdaq Noncompliance Notice | MT |
| Mar. 19 | Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 178.4 | 192.9 | 103.5 | 23.53 | 12.76 | 12.76 |
| Enterprise Value (EV) 1 | 142.6 | 147.7 | 89.51 | 23.53 | 12.76 | 12.76 |
| P/E ratio | -6.91 x | -8.65 x | -2.23 x | -0.73 x | -0.29 x | -0.47 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.66 x | 1.5 x | 0.55 x | 0.5 x | 0.26 x | 0.21 x |
| EV / Revenue | 3.66 x | 1.5 x | 0.55 x | 0.5 x | 0.26 x | 0.21 x |
| EV / EBITDA | -31,367,726 x | 178,162,448 x | -6,197,921 x | - | - | - |
| EV / FCF | -24,510,615 x | -185,886,254 x | -4,198,819 x | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - |
| Price to Book | 2.98 x | 2.81 x | 3.8 x | - | - | - |
| Nbr of stocks (in thousands) | 19,861 | 21,861 | 22,511 | 27,082 | 27,866 | 27,866 |
| Reference price 2 | 8.982 | 8.826 | 4.598 | 0.8690 | 0.4580 | 0.4580 |
| Announcement Date | 4/23/20 | 4/15/21 | 3/30/22 | 5/16/23 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 40.48 | 48.78 | 128.4 | 189.9 | 47.47 | 48.62 | 59.5 |
| EBITDA | - | -5.687 | 1.083 | -16.7 | - | - | - |
| EBIT 1 | - | -18.68 | -19.7 | -46.03 | -36.77 | -42.55 | -39.6 |
| Operating Margin | - | -38.3% | -15.35% | -24.24% | -77.46% | -87.51% | -66.55% |
| Earnings before Tax (EBT) 1 | - | -20.7 | -21.1 | -46.88 | -38.6 | -48.63 | -45.38 |
| Net income 1 | - | -20.86 | -21.38 | -46.9 | -31.84 | -48.65 | -45.38 |
| Net margin | - | -42.75% | -16.65% | -24.7% | -67.07% | -100.05% | -76.27% |
| EPS 2 | -40.00 | -1.300 | -1.020 | -2.060 | -1.190 | -1.600 | -0.9700 |
| Free Cash Flow | - | -7.278 | -1.038 | -24.65 | - | - | - |
| FCF margin | - | -14.92% | -0.81% | -12.98% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/28/19 | 4/23/20 | 4/15/21 | 3/30/22 | 5/16/23 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 64.96 | 51.87 | 30.2 | 42.9 | 10.33 | 11.2 | - | 11.5 | 12.5 | 14 | 14.5 | 15 |
| EBITDA | 0.698 | -2.066 | -12.68 | -2.654 | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.63 | -7.684 | -21.35 | -12.37 | - | -10.84 | - | -10.8 | -10.5 | -10.1 | -10 | -9.9 |
| Operating Margin | -7.13% | -14.81% | -70.69% | -28.83% | - | -96.76% | - | -93.91% | -84% | -72.14% | -68.97% | -66% |
| Earnings before Tax (EBT) 1 | -4.889 | -7.896 | -21.61 | -12.48 | - | -11.71 | - | -12.24 | -11.94 | -11.54 | -11.44 | -11.34 |
| Net income 1 | -4.889 | -8.222 | -21.61 | -12.3 | -6.482 | -10.35 | -24.46 | -12.24 | -11.94 | -11.54 | -11.44 | -11.34 |
| Net margin | -7.53% | -15.85% | -71.57% | -28.67% | -62.77% | -92.41% | - | -106.48% | -95.56% | -82.46% | -78.93% | -75.63% |
| EPS 2 | -0.2200 | -0.3700 | -0.9600 | -0.5100 | -0.2800 | -0.3800 | -0.8800 | -0.4400 | -0.3400 | -0.2700 | -0.2700 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 6/16/21 | 9/7/21 | 11/24/21 | 3/30/22 | 7/15/22 | 12/22/22 | 9/7/23 | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 35.8 | 45.3 | 14 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -7.28 | -1.04 | -24.7 | - | - | - |
| ROE (net income / shareholders' equity) | - | -35.4% | -34.1% | -101% | - | - | - |
| ROA (Net income/ Total Assets) | - | -17.7% | -16% | -38.9% | - | - | - |
| Assets 1 | - | 117.5 | 133.8 | 120.5 | - | - | - |
| Book Value Per Share | - | 3.010 | 3.140 | 1.210 | - | - | - |
| Cash Flow per Share | - | -0.4700 | 0.4000 | -0.9700 | - | - | - |
| Capex | - | 0.3 | 9.5 | 2.92 | 0.37 | - | - |
| Capex / Sales | - | 0.61% | 7.4% | 1.54% | 0.77% | - | - |
| Announcement Date | 3/28/19 | 4/23/20 | 4/15/21 | 3/30/22 | 5/16/23 | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.458
EUR
Average target price
1.378
EUR
Spread / Average Target
+200.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -59.26% | 13.62M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CNTG Stock
- Financials Centogene N.V.
